Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TLR4 | O00206 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2302998 | 0.98 | MAPT (0.45) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL16925438 | 0.90 | TLR4 (0.47) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL16925388 | 0.85 | MAPT (0.45) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL6346612 | 0.83 | MAPT (0.45) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL12426356 | 0.81 | CHRM3 (0.40) | ALDH1A1KMT2AKDM4EHSD17B10 | |
| SCHEMBL27894303 | 0.80 | MAPT (0.40) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL7517130 | 0.80 | TSHR (0.36) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL27753414 | 0.77 | — | — | |
| SCHEMBL1134463 | 0.77 | ALDH1A1 (0.53) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL11489301 | 0.77 | MAPT (0.46) | ALDH1A1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102746302-B | 1-substituted-3-benzyl-3, 6-diazabicyclo[3, 3, 1]nonane derivatives and preparation method | WUXI APPTEC WUHAN CO LTD | 2015-07-22 | — | — | CN | claimed |
| CN-102746302-A | 1-substituted-3-benzyl-3, 6-diazabicyclo[3, 3, 1]nonane derivatives and preparation method | WUXI APPTEC CO LTD | 2012-10-24 | — | — | CN | claimed |
| EP-4712961-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| EP-4665453-A1 | GPR65 MODULATORS | Pathios Therapeutics Limited (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250304574-A1 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | Pathios Therapeutics Limited (GB) | 2025-10-02 | — | — | US | disclosed |
| CN-111655695-B | Substituted furopyrimidine compounds as PDE1 inhibitors | 达特神经科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | DART NEUROSCIENCE LLC (US) | 2025-05-08 | — | — | US | disclosed |
| CN-119371403-A | Azaaromatic ring carboxamide compound and application thereof | 广州国家实验室 | 2025-01-28 | — | — | CN | disclosed |
| CN-115348959-B | Heteroaryl compounds and their therapeutic use in conditions associated with altered beta-glucocerebrosidase activity | GT增益治疗股份有限公司 | 2025-01-07 | — | — | CN | disclosed |
| US-20240417389-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2024-12-19 | — | — | US | disclosed |
| WO-2024238633-A2 | KRAS G12S AND G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2024-11-21 | — | — | WO | disclosed |
| US-7160886-B2 | Acylated piperazine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2007-01-09 | — | — | US | disclosed |
| US-6949546-B2 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2005-09-27 | — | — | US | disclosed |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | KO SOO S (US) | 2004-03-25 | — | — | US | disclosed |
| US-6627629-B2 | Useful for the treatment or prevention of asthma and other allergic diseases. | BRISTOL-MYERS SQUIBB PHARMA | 2003-09-30 | — | — | US | disclosed |
| CN-1440402-A | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2003-09-03 | — | — | CN | disclosed |
| EP-1296978-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB PHARMA COMPANY | 2003-02-13 | — | — | US | disclosed |
| WO-2002002525-A2 | N-UREIDOHETEROCYCLOAKLYL-PIPERIDINES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| EP-0092391-A2 | Novel piperidine derivatives and pharmaceutical compositions containing same | KYOWA HAKKO KOGYO CO., LTD (JP) | 1983-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240417389-A1 | PYRIMIDINYL TYROSINE KINASE INHIBITORS | ABL1, BTK, ABL2 | ALDH1A1 3713/4885MAPT 4498/4885MEN1 3197/4885 |
| US-20040058961-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | ALDH1A1 1357/4885MAPT 4623/4885MEN1 4772/4885 |
| US-20030032654-A1 | N-ureidoheterocycloalkyl-piperidines as modulators of chemokine receptor activity | CCR3, CCR1, ACKR3 | ALDH1A1 1357/4885MAPT 4623/4885MEN1 4772/4885 |
| US-20250145633-A1 | SUBSTITUTED FURANOPYRIMIDINE COMPOUNDS AS PDE1 INHIBITORS | PDE4A, PDE5A, PDE3A | ALDH1A1 87/4885MAPT 1815/4885MEN1 1930/4885 |
| US-20250304574-A1 | 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES | GPR65, GPR52, GPR68 | ALDH1A1 2702/4885MAPT 4817/4885MEN1 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.